Integrating Radiomics and Deep-Learning for Prognostic Evaluation in Nasopharyngeal Carcinoma
- PMID: 40731938
- PMCID: PMC12300200
- DOI: 10.3390/medicina61071310
Integrating Radiomics and Deep-Learning for Prognostic Evaluation in Nasopharyngeal Carcinoma
Abstract
Nasopharyngeal carcinoma (NPC) represents a prevalent malignant tumor within the head and neck region, and enhancing the precision of prognostic assessments is a critical objective. Recent advancements in the integration of artificial intelligence (AI) and medical imaging have spurred a surge in research focusing on NPC image analysis through AI applications, particularly employing radiomics and artificial neural network approaches. This review provides a detailed examination of the prognostic advancement in NPC, utilizing imaging studies based on radiomics and deep learning techniques. The findings from these studies offer a promising outlook for achieving exceptionally precise prognoses regarding survival and treatment responses in NPC. The limitations of existing research and the potential for further application of radiomics and deep learning in NPC imaging are explored. It is recommended that future research efforts should aim to develop a comprehensive, labeled dataset of NPC images and prioritize studies that leverage AI for NPC screening.
Keywords: artificial intelligence; deep learning; nasopharyngeal carcinoma; prognosis; radiomics.
Conflict of interest statement
The authors declare no conflict of interest.
Similar articles
-
Artificial intelligence-assisted detection of nasopharyngeal carcinoma on endoscopic images: a national, multicentre, model development and validation study.Lancet Digit Health. 2025 Jun;7(6):100869. doi: 10.1016/j.landig.2025.03.001. Epub 2025 Jun 20. Lancet Digit Health. 2025. PMID: 40544083
-
Artificial Intelligence-Driven Radiomics in Head and Neck Cancer: Current Status and Future Prospects.Int J Med Inform. 2024 Aug;188:105464. doi: 10.1016/j.ijmedinf.2024.105464. Epub 2024 Apr 23. Int J Med Inform. 2024. PMID: 38728812
-
Radiomics of pituitary adenoma using computer vision: a review.Med Biol Eng Comput. 2024 Dec;62(12):3581-3597. doi: 10.1007/s11517-024-03163-3. Epub 2024 Jul 16. Med Biol Eng Comput. 2024. PMID: 39012416 Free PMC article.
-
Diagnostic accuracy of radiomics and artificial intelligence models in diagnosing lymph node metastasis in head and neck cancers: a systematic review and meta-analysis.Neuroradiology. 2025 Feb;67(2):449-467. doi: 10.1007/s00234-024-03485-x. Epub 2024 Nov 11. Neuroradiology. 2025. PMID: 39527265 Free PMC article.
-
Predicting progression-free survival using dynamic contrast-enhanced imaging-based radiomics in advanced nasopharyngeal carcinoma patients treated with nimotuzumab.Eur Radiol. 2025 Aug;35(8):5135-5145. doi: 10.1007/s00330-025-11433-3. Epub 2025 Feb 14. Eur Radiol. 2025. PMID: 39953153
References
-
- Bossi P., Chan A., Licitra L., Trama A., Orlandi E., Hui E., Halámková J., Mattheis S., Baujat B., Hardillo J., et al. Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann. Oncol. 2021;32:452–465. doi: 10.1016/j.annonc.2020.12.007. - DOI - PubMed
-
- Pfister D.G., Spencer S., Adelstein D., Adkins D., Anzai Y., Brizel D.M., Bruce J.Y., Busse P.M., Caudell J.J., Cmelak A.J., et al. Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Canc Netw. 2020;18:873–898. doi: 10.6004/jnccn.2020.0031. - DOI - PubMed
-
- Sun X., Su S., Chen C., Han F., Zhao C., Xiao W., Deng X., Huang S., Lin C., Lu T. Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma: An analysis of survival and treatment toxicities. Radiother. Oncol. 2014;110:398–403. doi: 10.1016/j.radonc.2013.10.020. - DOI - PubMed
-
- Lee N., Harris J., Garden A.S., Straube W., Glisson B., Xia P., Bosch W., Morrison W.H., Quivey J., Thorstad W., et al. Intensity-Modulated Radiation Therapy With or Without Chemotherapy for Nasopharyngeal Carcinoma: Radiation Therapy Oncology Group Phase II Trial 0225. J. Clin. Oncol. 2009;27:3684–3690. doi: 10.1200/JCO.2008.19.9109. - DOI - PMC - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources